Barjesh Chander Sharma, MD, DM 1, Praveen Sharma, MD, DM 2, Manish Kumar Lunia, MD 1, Siddharth Srivastava, MD, DM 1, Rohit Goyal, MD, DM 1 and S.K. Sarin,

Slides:



Advertisements
Similar presentations
Maenne Okunola Pharm D. Candidate: University of Georgia June 2012 Preceptor: Dr. Ali Rahimi.
Advertisements

Acute Liver Failure.
DrMohammadSadrkabir Editor:. FREQUENCY OF ELEVATED HEPATOCELLULAR CARCINOMA (HCC) BIOMARKERS IN PATIENTS WITH ADVANCED HEPATITIS C The American Journal.
Treatment of Hepatic Encephalopathy Sepehr Khashaei, MD Department of Internal Medicine 11/5/10.
Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.
Role of Cilostazol in Stroke Prevention Philippine Heart Association 43 rd Annual Convention & Scientific Meeting Landmark Trials Session May 24, 2012.
EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C FOR SEVERE SEPSIS (PROWESS) GORDONR. BERNARD, M.D. et al. The New England Journal of Medicine.
Management of Hepatic Encephalopathy in the Hospital
Journal club April 2010 Dr Aucamp Dr Buchel Rifaximin treatment in hepatic encephalopathy.
Hepatic Encephalopathy in End-Stage Liver Disease Megan Dudley End of Life Care for Adults and Families The University of Iowa College of Nursing 1.
Curtis Nordstrom, M.S. MS-3/6 – Medical University of Sofia Sofia, Bulgaria.
Sarah Struthers, MD March 19, 2015
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Assessment of Efficacy and Safety for Exanta (Ximelagatran) Ruyi He, M.D. Medical Team Leader The Division of Gastrointestinal and Coagulation Drug Products.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division, Department of Medicine in King Saud University.
1 1 Zelnorm ® (tegaserod maleate) Advisory Committee Presentation Gastrointestinal Drugs July 14, 2004.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Acute On Chronic Liver Failure- Evolution of Concept 23 October 2015.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
Poster Design & Printing by Genigraphics ® A Comparison of the Effects of Etomidate and Midazolam on the Duration of Vasopressor Use in.
Copenhagen University Hospital Rigshospitalet, Denmark
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Journal Club Leona Isabella von Köckritz.
Clinicaloptions.com/hepatitis HALT-C: Long-term Maintenance Peginterferon alfa-2a Slideset on: Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis.
Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease : The St Francis Heart Study Randomized Clinical Trial Temitope Foster,
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
INTERNAL MEDICINE BENJAMIN YIP 4/13/16 Mini Lecture: Hepatorenal Syndrome.
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven.
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.
Randomized, Double-Blind, Controlled Study of Glycerol Phenylbutyrate in Hepatic Encephalopathy HEPATOLOGY 2014;59: 전임의 1 년차 신재령.
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis.
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Fekri Abroug, Lamia Ouanes-Besbes, Mohamed Fkih-Hassen, Islem Ouanes, Samia Ayed, Laurent Brochard and Souheil ElAtrous Prednisone in COPD exacerbation.
An AKI project for critically ill cancer patients
Clinical Trial Commentary
Alessandra Gennari, MD PhD
Gerova V., V. Nakov, L. Tankova, P. Penchev, R. Nakov
Todd W. Rice, MD, Gordon R. Bernard, MD 
STOPAH Trial Parth Kothari, MS3
Liver Disease tutoring Part 2
Study Trial design No. of patients Randomisation Outcomes assessed
Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial  Sudhir Maharshi, Barjesh Chander.
Copenhagen University Hospital Rigshospitalet, Denmark
James M. Roberts, M.D., Leslie Myatt, Ph.D.,et al.
GASTROENTEROLOGY 2009;137:892–901 R2. 정 회 훈.
L-Ornithine L-Aspartate in Bouts of Overt Hepatic Encephalopathy
DIAGNOSIS OF CIRRHOSIS
Hepatic Encephalopathy protocol - EMB review
Management of Hepatic Encephalopathy in the Hospital
CLINICAL SIGNIFICANCE AND
2010/10/14 Presented by R4 謝岳哲 Supervisor VS 薛承君 Moderator VS 黃集仁
COMPLICATIONS OF CIRRHOSIS
Cláudia Fagundes, MD, Pere Ginès, MD, PhD 
The Safety and Efficacy of Full vs
Opioids in Butte County
Volume 139, Issue 4, Pages e1 (October 2010)
Monthly Journal article review: Vimmi Kang PGY 2
Alcoholic Hepatitis (1)
Volume 142, Issue 3, Pages e1 (March 2012)
Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial  Sudhir Maharshi, Barjesh Chander.
Volume 136, Issue 7, Pages (June 2009)
Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care  Marc Cohen, MD  Mayo Clinic Proceedings 
Persistent Hyperammonemia Is Associated With Complications and Poor Outcomes in Patients With Acute Liver Failure  Ramesh Kumar, Shalimar, Hanish Sharma,
Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo  Barjesh Chander Sharma, Praveen.
Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial  Manish Kumar Lunia, Barjesh Chander Sharma, Praveen.
PRESENTER: Quynh vu, pgy-2
LIVER CIRRHOSIS IN PSC: DIAGNOSIS AND MANAGEMENT
Presentation transcript:

Barjesh Chander Sharma, MD, DM 1, Praveen Sharma, MD, DM 2, Manish Kumar Lunia, MD 1, Siddharth Srivastava, MD, DM 1, Rohit Goyal, MD, DM 1 and S.K. Sarin, MD A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy R1. 박은지 / Pf. 심재준 THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 108, 23 July 2013

Introduction Hepatic encephalopathy (HE) ; complication of advanced liver disease → 30 to 45 % of LC ; reversible disorder The primary treatment of HE ; elimination of the increased neurotoxic ammonia levels 1) Lactulose BUT) evidence supporting its efficacy limited !! 2) Rifaximin In randomized studies, more effective than lactulose Equivalent ~ greater than other antibiotics used in acute HE → Evaluation of a combination of rifaximin + lactulose ??

Objective - prospective double-blind randomized controlled trial - Enrolled duration; ~ Age; 18~ 80 years - LC c over HE Exclusion - sCr > 1.5 mg / dl on admission - Active alcohol intake < 4 weeks before present episode - HCC - Other metabolic encephalopathies - Degenerative CNS disease - Major psychiatric illness Methods (1)

Methods (2) Study design - Severity of HE was graded according to West Haven criteria - Utill complete recovery of HE (max; 10 days) - Cured → continued on same medications - Failed → Group A ; L-ornithine and L -aspartate Group B; Rifaximin GroupAGroupB Rifaximin 400mg tid Lactulose 30~60cc tid → Semisoft stool 2~3/day Placebo(sugar) tid Lactulose 30~60cc tid → Semisoft stool 2~3/day

Results (1) Figure 1. Total 172

Results (2)

Results (3)

Adm day A ; 5.8 ± 3.4 days B ; 8.2 ± 4.6 days → P = Decrease in mortality A ; 15 (24 % ) B ; 28 (49.1 %) → P < 0.05 Deaths d/t sepsis A ; 7 B ; 17 → P = 0.01 d/t GI bleeding A ; 4 B ; 4 → P = NS d/t Hepatorenal sdr A ; 4 B ; 7 → P = NS

Conclusion Combination of lactulose plus rifaximin is more effective than lactulose alone in the treatment of overt HE

Thank you !